Calidi Biotherapeutics (NYSEAMERICAN:CLDI) Receives New Coverage from Analysts at LADENBURG THALM/SH SH

LADENBURG THALM/SH SH started coverage on shares of Calidi Biotherapeutics (NYSEAMERICAN:CLDI) in a research report sent to investors on Thursday morning, MarketBeat Ratings reports. The brokerage issued a buy rating and a $1.00 price objective on the stock.

Several other analysts have also issued reports on the stock. HC Wainwright cut their target price on shares of Calidi Biotherapeutics from $11.00 to $2.00 and set a buy rating for the company in a research report on Thursday, March 21st. Robert W. Baird lowered their target price on shares of Calidi Biotherapeutics from $4.50 to $2.00 and set an outperform rating on the stock in a report on Wednesday, May 15th.

Calidi Biotherapeutics Stock Performance

Shares of Calidi Biotherapeutics stock opened at $0.20 on Thursday. Calidi Biotherapeutics has a 52-week low of $0.14 and a 52-week high of $13.79.

Calidi Biotherapeutics (NYSEAMERICAN:CLDI) last released its quarterly earnings data on Tuesday, May 14th. The company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.07. Equities research analysts predict that Calidi Biotherapeutics will post -0.37 EPS for the current fiscal year.

Institutional Investors Weigh In On Calidi Biotherapeutics

A number of hedge funds have recently bought and sold shares of the business. Spectrum Asset Management Inc. NB CA purchased a new stake in Calidi Biotherapeutics during the first quarter valued at $94,000. Apollo Management Holdings L.P. purchased a new stake in shares of Calidi Biotherapeutics in the first quarter valued at $71,000. Evermay Wealth Management LLC purchased a new stake in shares of Calidi Biotherapeutics in the first quarter valued at $36,000. Finally, Magnetar Financial LLC purchased a new stake in shares of Calidi Biotherapeutics in the first quarter valued at $36,000. Hedge funds and other institutional investors own 12.53% of the company’s stock.

About Calidi Biotherapeutics

Calidi Biotherapeutics, Inc, a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors.